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Abstract
Background: VEGF proteolysis by plasmin or matrix metalloproteinases (MMPs) is believed to play an important role in
regulating vascular patterning in vivo by releasing VEGF from the extracellular matrix (ECM). However, a quantitative
understanding of the kinetics of VEGF cleavage and the efficiency of cell-mediated VEGF release is currently lacking. To
address these uncertainties, we develop a molecular-detailed quantitative model of VEGF proteolysis, used here in the
context of an endothelial sprout.
Methodology and Findings: To study a cell’s ability to cleave VEGF, the model captures MMP secretion, VEGF-ECM binding,
VEGF proteolysis from VEGF165 to VEGF114 (the expected MMP cleavage product of VEGF165) and VEGF receptor-mediated
recapture. Using experimental data, we estimated the effective bimolecular rate constant of VEGF165 cleavage by plasmin to
be 328 M
21s
21 at 25uC, which is relatively slow compared to typical MMP-ECM proteolysis reactions. While previous studies
have implicated cellular proteolysis in growth factor processing, we show that single cells do not individually have the
capacity to cleave VEGF to any appreciable extent (less than 0.1% conversion). In addition, we find that a tip cell’s receptor
system will not efficiently recapture the cleaved VEGF due to an inability of cleaved VEGF to associate with Neuropilin-1.
Conclusions: Overall, VEGF165 cleavage in vivo is likely to be mediated by the combined effect of numerous cells, instead of
behaving in a single-cell-directed, autocrine manner. We show that heparan sulfate proteoglycans (HSPGs) potentiate VEGF
cleavage by increasing the VEGF clearance time in tissues. In addition, we find that the VEGF-HSPG complex is more
sensitive to proteases than is soluble VEGF, which may imply its potential relevance in receptor signaling. Finally, according
to our calculations, experimentally measured soluble protease levels are approximately two orders of magnitude lower than
that needed to reconcile levels of VEGF cleavage seen in pathological situations.
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Introduction
The cytokine vascular endothelial growth factor A (VEGF) is a
critical mediator of adult neovascularization. Inducing blood vessel
growth can be beneficial in alleviating tissue ischemia and in
synthetic graft acceptance; however, neovascularization is also
responsible for supporting pathological processes such as tumor
growth. Controlling the activity of VEGF is thus an area of
significant interest.
VEGF activity and patterning in tissues is regulated by its
binding to the extracellular matrix (ECM), which is determined
both by alternate splicing of VEGF and by processing of VEGF
and the ECM by proteases and heparinases, resulting in a range of
vascular phenotypes [1–5]. Alternate splicing results in isoforms of
various lengths, the most actively expressed in humans being
VEGF121, VEGF165, and VEGF189. The longer VEGF isoforms
contain basic residues encoded by exons 6 and/or 7 of the VEGF
gene, which results in differential binding to VEGF receptors
(VEGFRs), Neuropilin-1 (NRP1) [6,7], and to various ECM
molecules including collagen, fibronectin, fibrinogen, and fore-
most, glycosaminoglycans, found in heparan sulfate proteoglycans
(HSPGs) [1,8–12]. ECM binding may regulate VEGF-dependent
vascular patterning by controlling VEGF diffusion and gradients
through tissues [5,13] and possibly by mediating solid-state
binding to VEGFRs [3,14–16].
Proteolytic release of VEGF, also referred to as VEGF release
(as distinct from secretion of the unproteolyzed ligand by cells), can
occur by cleavage of matrix-bound VEGF at its C-terminal
domain or by cleavage of the ECM and results in a diffusible
VEGF [1,3,8,17,18]. VEGF release is thought to increase the
soluble VEGF concentration, potentiating the angiogenic switch
and leading to neovascularization and tumor growth [1,8,18,19],
but in some cases, it impairs angiogenesis [3,20,21] and deters
tumor progression [3].
VEGF cleavage can occur readily via the proteases plasmin,
MMPs, and elastase [3,6,17,20,22]. The structural requirements
for VEGF cleavage are not currently well understood. While
human VEGF isoforms are susceptible to proteolysis by plasmin
[3,6,14,23], they do not seem to be susceptible to the MMPs
[8,22,24]. On the other hand, murine VEGF, e.g. VEGF164, the
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most potent being MMPs -3, -7, -9, -12, and -19 [3,17]. HSPGs
seem to protect VEGF against some proteases, e.g. MMP9, but
not against others, e.g. MMP3 [3].
VEGF release occurring through the cleavage of the ECM can
occur through proteoglycan core protein digestion by plasmin,
elastase, or a subset of the MMPs (e.g. MMPs -3, -9, -13, but not
MMP2) [1,8,9,25,26]; or through GAG cleavage by heparinases
[9,27]. In tissue engineering applications, VEGF variants can be
covalently tethered to matrices such as fibrin and polyethylene
glycol [14,28] to be protected against rapid diffusive clearance and
allow VEGF release in a cell-mediated, matrix-coupled fashion
[29]. It is not currently known whether VEGF cleavage or ECM
cleavage is the predominant mechanism of VEGF release. Lee et
al. [3] show evidence for the former, both in tumor xenografts and
in an in vitro endothelial cell spheroid model, while Hawinkels et al.
[8] demonstrate that MMP9 cleaves HSPGs to mediate the VEGF
release-dependent angiogenesis of colon tumor explants.
Much remains to be determined about the nature of VEGF
proteolysis and cell-mediated release. For example, endothelial
cells [3,19], neutrophils [30], and macrophages [17,30–32] all
have been implicated as potential mediators of VEGF release, but
when each cell type is important is not known. Thus the question
of when VEGF release is an autocrine or paracrine process has not
been answered. In addition, the extent of VEGF release is system-
dependent. Lee et al. reported that in the serum of mice implanted
with fibrosarcoma, over 80% of circulating VEGF is in a cleaved
form [3], a value similar to that in retinal tissue of mice with
oxygen-induced retinopathy [17]. A lower, but still significant
value of ,30% cleaved VEGF was detected in human ovarian
tumor lysates [33]. In contrast, in an in vitro fibrin-based system, a
significant release-dependent cellular response occurred without
any detectable VEGF release [14]. We do not currently know the
rate at which VEGF release or cleavage occurs in biology.
Experiments treating growth factors with exogenous protease show
that 20 min with 400 nM plasmin [2,6,34], 30 min with 20 mM
elastase [35], or 24 h with ,0.3 to 20 nM active MMP9 [1,8] all
carry significant proteolytic potential. However, in vivo protease
levels in plasma and in pathological fluid samples are typically
lower, between 100 pM–20 nM [36–41], while clearance rates for
VEGF (after accounting for its proteolytic degradation) are very
rapid, ,1 h [42]. It is not currently known if these protease
levels are sufficient to account for the .80% circulating cleaved
VEGF [3].
The efficiency of VEGF cleavage and release may be tied to
intense but tightly localized pericellular events (difficult to detect
using standard experimental techniques lacking spatial resolution)
[3,19,43]. Numerous studies have shown proteases to be tightly
localized around cells, through cell-surface molecules such as
a2(IV), CD44, or LRP [44,45]. Tight cell-surface or pericellular
localization is known to improve protease activation [46] and
reduce inhibition [47,48], and thus may increase proteolysis of the
ECM and of soluble growth factors, e.g. transforming growth
factor-b and VEGF [3,45,49–51]. Indeed, our computational
model has previously demonstrated that cell-surface MT1-MMP
plays an important role in sprout migration [50]. Proteases may be
further localized in an individual cell to distinct cell-surface
microdomains, e.g. focal adhesions, which may enhance their
activity. However, other studies show that it is interstitial proteases
and not cell-surface proteases that are important in VEGF release
and gradient formation [19,52].
Quantitative understanding of these processes is essential to
determine their relative importance in vivo. For example, while it is
generally assumed that matrix binding localizes a growth factorto the
ECM, generating local deposits of VEGF [5,53], growth factor-ECM
complexes can rapidly dissociate (koff=0.01s
21) [54] and are thus
highly dynamic, a criterion which affects the cleavage of VEGF. A
central goal in this study is to determine the extent to which VEGF
release is a cell-directed and localized or autocrine process.
Computational and mathematical models by other groups have
suggested that autocrine signaling of growth factors is feasible with
low cytokine diffusivity in biological matrices [55] and that interstitial
flow can generate protease-induced autocrine VEGF gradients [19].
Experimentally, MMPs have been shown to modulate growth factor
signaling at the single cell level by directing lateral inhibition during
b r a n c h i n gm o r p h o g e n e s i s[ 5 6 ] .I ti sa l s oo f t e nt h o u g h tt h a tas i n g l e
cell has sufficient proteolytic capacity to alter the VEGF distribution
[19,53,57]. Here, we study the capacities of an endothelial tip cell to
cleave VEGF and to recapture released VEGF, as well as determine
whether known protease levels can result in the VEGF conversion
levels (the ratio of cleaved VEGF to total soluble VEGF) observed
both in vivo and in vitro.
To clarify the process of VEGF release, we develop a molecular-
detailed quantitative model of VEGF cleavage based on an
endothelial tip cell cleaving and releasing nearby VEGF. This
model extends our efforts to quantify the interactions between
VEGF, VEGF receptors, and the MMP systems to mechanistically
understand angiogenesis and drug treatments to reduce angiogen-
esis in pathological situations [50,58–67]. Using experimental data,
we estimate rate constants for the proteolytic cleavage of VEGF by
plasmin and specify protease secretion rates by a tip cell. We
characterize the extent of VEGF cleavage as well as the cellular and
tissue determinants of proteolytic VEGF release. We simulate tip
cell-mediated redistribution of VEGF in tissues and compare the
results with experimental data [19,53]. The model includes both
VEGF-HSPG binding and the VEGF-VEGFR interactions to
simulateautocrinecapture.Thepresentmodelisspecificallyapplied
to the geometry of a protease-secreting endothelial tip cell, however
our model is extendable to any cell type.
Methods
Model Formulation
We developed a computational model to calculate the proteolytic
cleavageofVEGFbyaprotease-secretingendothelialsprout(Fig.1).
Weconsider a region oftissue activelyundergoing angiogenesiswith
numerous sprouts projecting towards a distant VEGF source, e.g. a
tumor; our model system focuses on one of those sprouts, to capture
the behavior of proteases and VEGF around it. We included only
one VEGF isoform, VEGF165; its transport includes diffusion,
protease interactions, and binding to HSPGs and VEGFRs (which
mediate cellular internalization of VEGF). The sprout, idealized as
a cylinder, consists of a single tip cell followed by stalk cells, is
surrounded by a thin basement membrane (BM), and is immersed
in a volume of ECM. We assume that the endothelial tip cell is
‘‘activated’’ and can secrete a generic protease capable of cleaving
both free and ECM-bound VEGF165 into VEGF114. Along with
diffusion of protease, VEGF165, and VEGF114, the model simulates
the following reactions:
Volumetric Reactions (ECM and BM)
VEGF165 + HSPG « VEGF165?HSPG
VEGF165 + Protease R VEGF114 + Protease
VEGF165?HSPG + Protease R VEGF114 + Protease + HSPG
Cell-surface (Heterogeneous) Reactions (BM only)
VEGF165 + VEGFR2 « VEGF165?VEGFR2
VEGF114 + VEGFR2 « VEGF114?VEGFR2
VEGF Release Model
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kinetic rate constants for association and dissociation. VEGF165
binding to HSPGs is modeled as a single-step reaction [54]. While
VEGF165 cleavage to VEGF114 is in reality a two-step reaction [6]
occurring through the intermediate heterodimer, VEGF165-114,w e
assume an effective single cleavage step (justified in Supplement S1,
section S1; Fig. S1B). VEGFR2 is inserted into and internalized from
the cell surface. Protease is secreted into the basement membrane
layer and diffuses out into the ECM volume (Fig. 1). For simplicity,
we assume that the secreted protease is active, i.e. we ignore the
dynamics of its activation and inhibition, which we have previously
characterized for MMP9 and MMP2 [50,58,59]. In this model, we
are primarily interested in characterizing the extent of VEGF
cleavage at steady-state. Our calculations proceed in two steps:
first to calculate the VEGF distribution before the secretion of
proteases and then incorporate protease secretion and VEGF
proteolysis until a final steady state is reached.
For simplicity our current model does not incorporate VEGFR1
or NRP1, receptors for which we have previously developed
biochemically-detailed models [62], as we assume receptor binding
primarily plays a sensory role and the model instead focuses on
characterizing VEGF proteolysis. We note that one of our results is
concerned with the autocrine capture of VEGF, for which we also
test the role of VEGFR1 and NRP1 and thus provide a full
reaction formulation for reference in Supplement S1, section SII,
which follows [68]. Similarly, we also test whether NRP1 affects
the assumption of VEGF proteolysis occurring in a single step
(Supplement S1, section SIII; Fig. S2).
The basement membrane covering vessels may not always be
structurally integral, e.g. in tumors [69]. In addition, for a nascent
sprout, basement membrane deposition by the sprout lags the
sprout’s migration resulting in basement membrane coverage over
the entire sprout except for the tip cell, as visualized in [70]. In our
model, we assumed a complete basement membrane over the
entire sprout as a reference case; we also tested the effects of
varying basement membrane thickness and partial tip cell
basement membrane coverage and found the effect of basement
membrane coverage to be negligible. The ECM and basement
membrane were treated as porous media due to the presence of
fibrillar components. The porous material property of interest, the
available volume fraction, Kav, represents the fraction of space that
is accessible to a molecule for diffusion and depends on the
molecule’s size and matrix fiber composition [71,72]. As a result,
the concentration of a molecular species in the interstitial fluid,
Cfluid, or ‘‘local’’ concentration, differs from the volume-averaged
‘‘bulk’’ concentration, Cbulk, of the species in a tissue by the
relation Cbulk=C fluid?Kav. The ECM and basement membrane
are physically distinct, which is reflected in our model by different
values for the protein diffusivities, Kav, HSPG density, and reactive
components (see Methods, Parameters). While our governing
equations are formulated in terms of bulk concentrations, we will
refer to a species’ interstitial fluid concentration in our results and
figures unless explicitly stated.
VEGF/Protease Transport and Reactions in the ECM
Our system is formulated mathematically as reaction-diffusion
partial differential equations:
L½C 
Lt
~{DC+2½C zRC ð1Þ
where DC is the effective diffusivity of a molecular species C in the
porous environment and [C] is the bulk or pore-averaged
concentration of C. For each species, these differential equations
(Eqns. 2–6) are coupled to their appropriate boundary conditions
(see Methods, External Boundary Conditions and Methods, Reactions at
Vessel Boundary).
We first consider the transport of VEGF165 in the domain:
L½V165 
Lt
~D165+2½V165 {
kon
KECM
½V165 ½H zkoff½V165H 
{
kP
KECM
½V165 ½P 
ð2Þ
Figure 1. Schematic of computational model. VEGF is represented as either VEGF165 (green) or VEGF114 (orange), and secreted protease as P
(light blue). VEGF165 is able to diffuse and bind HSPG, bind to VEGF receptors, or become proteolyzed by proteases secreted by the tip cell of the
endothelial sprout. Computationally, the sprout is located in the ECM volume but is surrounded by a narrow basement membrane. The matrix
molecule of importance in the present model is the HSPG, which is able to reversibly bind VEGF. Protease is assumed to catalyze the conversion of
VEGF165 to VEGF114 in a one-step reaction (see text). For simplicity, our model considers only a single VEGF receptor, VEGFR2.
doi:10.1371/journal.pone.0011860.g001
VEGF Release Model
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the HSPG, while kP denotes the effective bimolecular rate constant
of proteolysis between VEGF165 and protease, given by [P].
VEGF114 is generated from cleavage of either free or matrix-
bound VEGF165 [3]:
L½V114 
Lt
~D114+2½V114 z
kP
KECM
½V165 ½P z
kP
KECM
½V165H ½P ð 3Þ
A C-terminal fragment of VEGF is also produced from cleavage
by plasmin and while it has affinity to the matrix [6], its effects can
be neglected as its concentration is much less ([V],1 pM [73])
than the Kd of matrix interaction, and thus does not saturate
existing binding sites.
Our estimated Km of VEGF proteolysis by plasmin (.1 mM,
see Supplement S1, section SI) is much larger than the VEGF
concentration and allows us to use first-order, rather than
Michaelis-Menten, kinetics for the cleavage and neglect changes
in the protease concentration due to VEGF binding. To account
for possible protease inactivation due to inhibition or degradation,
we impose an autolytic degradation rate constant, kdeg. Thus, the
protease distribution after its secretion is governed by:
L½P 
Lt
~DP+2½P {kdeg½P ð 4Þ
The matrix components, HSPG ([H]) and VEGF165-HSPG
([V165H]), are described as ordinary differential equations (ODEs)
since they do not diffuse but do interact with VEGF and protease:
d½H 
dt
~{
kon
KECM
½V165 ½H zkoff½V165H z
kP
KECM
½V165H ½P ð 5Þ
d½V165H 
dt
~
kon
KECM
½V165 ½H {koff½V165H {
kP
KECM
½V165H ½P ð 6Þ
External boundary conditions for VEGF secretion and
interstitial clearance
Typically, boundary conditions are imposed by specifying either
the concentration or the flux at each face. We assume a cylindrical
coordinate system and thus must specify four external boundary
conditions: the leading face, z=+L; trailing face, z=2L; radial
edge, r=R; and the central axis in the region excluding the sprout,
i.e. r=0 and z.0 (see Fig. 1). The vessel surface boundary is
considered in the next section.
For the central axis (r=0), we have hV/hr=0 due to symmetry.
We consider two cases of the model:
Case 1: The sprout is considered in isolation, with an imposed
background of VEGF or protease. Thus we use a Dirichlet
boundary condition: [V165]=V 0,[ V 114]=0, and [P]=P0 at all
outer boundaries, r=R and z=6L.
Case 2: The sprout is considered as one of many sprouts
migrating up an imposed gradient of VEGF. The computational
domain is assumed representative of its surrounding tissue in the
radial direction. Thus, we use a no-flux condition, hV/hr=0 at
r=R. With the VEGF gradient in the z-direction, Dirichlet
boundary conditions would overestimate VEGF diffusion through
the boundaries (tDiffusion,L
2/D,1.5 min) compared to in vivo
clearance rates on the order of hours [42]. Thus, Neumann
boundary conditions were used to specify the VEGF165 secretion
rate from the surface z=+L: 2D?h[V165]/hz=2q, which was
balanced by a first-order VEGF clearance at z=2L, 2D?h[V165]/
hz=2kclear[V165]. The secretion rate q and kclear were pre-
calculated to give the desired VEGF concentration in the absence
of proteases, V0 at z=0 and VEGF gradient, g0 over the domain
length (see Methods, Model Implementation). For VEGF114, h[V114]/
hz=0atz=+L (no secretion), and 2D?h[V114]/hz=2kclear[V114]
at z=2L. The overall clearance rate, kclear/(2?L) ,5.41?10
24 s
21,
is similar in magnitude to clearance times in vivo [42] and represents
receptor-mediated internalization by the pre-existing vasculature
andtransvascularpermeability. Forsimplicity, we assume a uniform
protease distribution. While protease patterning would affect the
resulting VEGF distribution, we are mainly interested in the degree
of VEGF cleavage brought about by the mean protease level, and
not in the specific shape of VEGF gradients, which may depend on
which cells secrete proteases and where.
Reactions at Vessel Boundary and Transport in the
Basement Membrane
Basement membranes around vessels are thin (,43 nm [74]).
Thus, the diffusive hindrance over the basement membrane layer’s
length is formulated as a lumped boundary condition such that at
the transition between the ECM and basement membrane layer,
both the interstitial fluid concentrations of solutes and the total
diffusive fluxes (given by Jout) are continuous (refer to Supplement S1,
section SIV):
½C
Local
BM  Dinterface~½C
Local
ECM Dinterface
KBM
KECM
ð7Þ
J
I
out~{DBM
C
L½C
Local
BM  
Ln
~{DECM
C
L½C
Local
ECM 
Ln
ð8Þ
Cell-surface reactions are assumed to occur in the basement
membrane volume and lateral diffusion along the cell surface is
negligible (D,10
22 mm
2/s [75]; Damkohler number, Da=
koff?Lsprout
2/D=160). As a result, the cell-surface distributions of
soluble species and receptors can be approximated by ordinary
differential equations (Eqns. 9–16)
d½V165 
dt
~{
JV165
out
dBM
zkoff½V165H {
kon
KBM
½V165 ½H {
kP
KBM
½P ½V165 
{
k
165,R2
on
KBM
½V165 
½R2 
dBM
zk
165,R2
off
½V165R2 
dBM
ð9Þ
d½V114 
dt
~{
JV114
out
dBM
z
kP
KBM
½P ½V165 z
kP
KBM
½P ½V165H 
{
k
114,R2
on
KBM
½V114 
½R2 
dBM
zk
114,R2
off
½V114R2 
dBM
ð10Þ
d½P 
dt
~
qP{JP
out{kdeg½P 
dBM
ð11Þ
We assume constant total HSPG concentration, with no
secretion by the endothelial cell. Similar to the case in the
VEGF Release Model
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d½H 
dt
~{
kon
KBM
½V165 ½H zkoff½V165H z
kP
KBM
½V165H ½P ð 12Þ
d½V165H 
dt
~
kon
KBM
½V165 ½H {koff½V165H {
kP
KBM
½V165H ½P ð 13Þ
Receptor and ligand-receptor complex distributions are also
assumed to be homogenous over the cell surface, i.e. we do not
include the effects of receptor clustering [76]. VEGFR2 is under
a constant flux of cell-surface expression (insertion) and
internalization, which we assume is independent of its binding
VEGF.
d½R2 
dt
~sR2{kint½R2 {
k
165,R2
on
KBM
½V165 z
k
114,R2
on
KBM
½V114 
 !
:½R2 
zk
V165,R2
off ½V165R2 zk
114,R2
off ½V114R2 
ð14Þ
d½V165R2 
dt
~{kint½V165R2 z
k
165,R2
on
KBM
½V165 ½R2 {k
165,R2
off ½V165R2 ð15Þ
d½V114R2 
dt
~{kint½V114R2 z
k
114,R2
on
KBM
½V114 ½R2 {k
114,R2
off ½V114R2 ð16Þ
It has been shown that VEGF110 (or VEGF114 in our case)
behaves similarly to VEGF121 [6], and thus its interactions with
VEGFR2 follow the same formulation as VEGF165 or VEGF121.
In the current model, we assume that only free VEGF can
interact with VEGF receptors. That is, VEGF165 bound to
HSPG in the basement membrane layer cannot interact with the
receptor population. The kinetic parameters describing these
reactions are described below (see Tables 1, 2). We will make
inferences about the possibility of matrix-sequestered VEGF
species interacting with VEGF surface receptors in the
Discussion.
Numerical Methods for VEGF Calculations
The computational domain was represented in cylindrical
coordinates and the VEGF and HSPG transport equations were
solved using the finite volume method on a 2D grid (z and r).
The basement membrane layer was used to approximate cell-
surface and basement membrane volume reactions. The control
volume spacing in the z-direction was 8 mm. In the r-direction,
one voxel was used to represent the sprout radius, from r=0 to
r=R sprout;f o rr $rsprout (outside the sprout surface), spacing was
4–8 mm .D u et ot h et h i n n e s so ft h eb a s e m e n tm e m b r a n el a y e r ,
its radial dimension was approximated by a single node. Jout,
previously given implicitly, was derived such that fluxes and
concentrations were continuous (refer to Supplement S1, section
SIV).
The first order derivatives in time were discretized using a first
order fully-implicit scheme, while second order spatial derivatives
used a central difference approximation. Nonlinear solution of the
equations was found by iteration using the successive over-
relaxation (SOR) update formulation and a Red-Black node
ordering [77]. Additional speedup was performed by setting the
initial guess for the solution of each time step as y
t+1=2?y
t2y
t21.
The convergence criteria at each time step was set to a maximum
fractional change in any computational node less than or equal to
10
27/iteration.
Table 1. Parameters of Model.
Definition Parameter Value Source
Kinetic Parameters
Association with VEGFR2 kon
114,R2,k on
165,R2 1?10
7 M
21s
21 [61]
Dissociation with VEGFR2 koff
114,R2,k off
165,R2 1?10
23 s
21 (Kd=100 pM) [61]
Internalization rate of VEGFR2 kint 2.8?10
24 s
21 [79]
Expression rate of VEGFR2 sR2 kint?[R2]Total {
Association with HSPG kon
165,H 4.2?10
5 M
21s
21 [54]
Dissociation with HSPG koff
165,H 0.01 M
21s
21 (Kd=24 nM) [54]
Cleavage rate of VEGF by Protease kP 631 M
21s
21, see Results [6,95]{
Secretion rate of Protease from tip cell qP 3?10
6 molecules/h (2.7?10
29 [mol/(10
15 mm
2?s)] [86]
Transport and Physical Parameters
Length of tip cell Ltip 40 mm [13]{
Radius of sprout Rsprout 2 mm [13]{
Area of tip cell surface Atip 515 mm
2 {
Basement membrane thickness dBM 0.043 mm [96]
Available volume fraction of ECM KECM 0.85 [71]{
Available volume fraction of BM KBM 0.20 [71]{
Diffusivity D165,D 114,D P 68.8 mm
2/s (ECM), 18.0 mm
2/s (BM) { see Methods
{Calculated.
{Estimated from Ref.
doi:10.1371/journal.pone.0011860.t001
VEGF Release Model
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The initial condition for the protease secretion simulations
consists of a fully-formed VEGF distribution after taking into
account VEGF depletion by receptor-mediated internalization.
For case 1, this consisted of finding the steady-state distribution in
the absence of protease secretion. In the case of an imposed VEGF
gradient (case 2), we used Neumann boundary conditions fitted to
produce a mean concentration, V0, and gradient, g0, and thus
required a sequence of simulation steps.
We first specified Dirichlet boundary conditions in the absence
of receptors to satisfy g0 (see Parameters) and the mean VEGF
concentration at z=0, V0:a tz=+L, [V165]=V 0?(1+g0?L/Ltip), at
z=2L, [V165]=V 0?(12g0?L/Ltip)). This was done in the absence
of HSPGs to allow faster convergence. After equilibration of the
VEGF receptor population, the Dirichlet boundary conditions
were converted into the appropriate ‘case 2’ boundary conditions
by calculating q and kclear using the following formulas,
q:
ð Redge
0
rdr~
ð Redge
0
D164
L½V164 
Lz D
z~zL
rdr ð17Þ
kclear:
ð Redge
0
½V164 rdr~
ð Redge
0
D164
L½V164 
Lz D
z~{L
rdr ð18Þ
and the system was solved until steady state was reached. Even
though these boundary conditions do not exactly specify the
conditions g0 and V0, this approximation is justified since the error
is small for our domain size and gradient. HSPGs were finally directly
imposed by the equilibrium relations [V165H]=[V]?[H]Total/
(Kd+[V]), as the distribution of soluble VEGF at steady state is
independent of HSPGs in the absence of proteases.
Geometrical and Transport Parameters
The domain sizes were L=Redge=1200 mm (case 1) and
L=80mm and Redge=50mm (case 2) (Fig. 1). The case 1
dimensions are large to study the impact of a single sprout in
isolation. The case 2 domain dimensions are representative of
mean sprout to sprout distance observed in retinal angiogenesis
studies (50–100 mm) [13] and mean neutrophil to neutrophil
distance in pancreatic islets (i.e. given a neutrophil frequency of
0.1% to 0.4%, neutrophil to neutrophil distance ,200 mm) [30],
as well as typical sprout tip cell lengths of 40 mm. In these
domains, the sprout is idealized as a cylinder from the surface
z=2L to z=0 of which the tip cell occupies from z=240 mmt o
z=0mm. The radius of the sprout cylinder is 2 mm [13].
The diffusivity and available volume fractions depend on the
structure of the interstitial matrix. We estimated diffusivities
directly from the properties of the ECM (collagen: v/v=14%,
fiber radius=20 nm; glycosaminoglycans: v/v=0.078%, effective
fiber radius=0.55 nm [78]) and estimates of interstitial protein
content (Supplement S1, section SV; Table S2). While the diffusivities of
various VEGF isoforms would be different in vivo, we assumed
each had a diffusivity equal to that of VEGF165. Available volume
fractions were taken as limiting cases for matrix connectivities as
derived in [71] (KECM=0.85, KBM=0.2).
Kinetic Parameters of Reactions
The kinetic parameters for VEGF binding to VEGFR2 have
been previously characterized [61], while VEGF165 binding to
HSPGs was assumed to be identical to that of bFGF [54]. To
characterize the kinetic rate constants of VEGF cleavage by
proteases, we assumed the following molecular weights: active
plasmin (86 kDa with commercial preparations containing 3 U/
mg); MMP3 and VEGF165, 45 kDa each. Plasmin and MMP3
seemed to have similar proteolytic strengths on a molar basis
(refer to supplement of [3]). One study indicated VEGF165
cleavage by plasmin (0.01 U/mL or ,40 nM) from zymographic
and VEGF mitogenicity data with a half-life of 1–4 h, equating to
kP ,1.2?10
3–5?10
3 M
21s
21 [34]. Our estimate of the rate of
VEGF165 cleavage by plasmin at 37uC( k p=631M
21s
21)w a s
derived by directly fitting kinetic data from Keyt et al. [6] to a
one-step cleavage model (described in Supplement S1, section S1; Fig.
S1A).
Table 2. Base Conditions.
Definition Parameter Value Source
Common Conditions
Total interstitial-fluid [HSPG] ECM [HECM]Total 0.75?10
26 mol/(10
15 mm
3) [97]
Total interstitial-fluid [HSPG] BM [HBM]Total 13?10
26 mol/(10
15 mm
3) [54]
Total VEGFR2 per cell [R2]Total 10,000/(area of tip cell) -i.e.- 3.22?10
28 [mol/10
15 mm
2] [61]
Case 1 (isolated cell)
Farfield [VEGF165]V 0 (farfield) 1 pM [73]
Farfield [Protease] P0 (farfield) 0 nM *
Length, Radius of cylindrical domain L, Redge 1200 mm, 1200 mm*
Case 2 (non-isolated cell)
Initial mean [VEGF165]V 0 1p M *
VEGF secretion rate on surface, z=+Lq V (z=+L) 7.68?10
25 molec/mm
2?s {
Fractional gradient at z=0 g0 0.05 *
Clearance rate on surface, z=2Lk clear 0.0866 mm/s *
Length, Radius of cylindrical domain L, Redge 80 mm, 50 mm*
{Calculated.
*Assumed.
doi:10.1371/journal.pone.0011860.t002
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Interstitial VEGF levels were previously reported at ,1p M
[73], while HSPG concentrations were taken from previous studies
at 750 nM in the ECM and 13 mM in the basement membranes
[61]. We assume that these concentrations refer to intra-pore
concentrations. Typical concentrations of VEGFR2 on abluminal
faces of endothelium were estimated in previous studies at ,10
4
VEGFR2/cell [79,80].
The level of active proteases in in vitro and in vivo biological
systems is not exactly known. MMP and plasmin concentrations in
the circulation have been determined previously to be ,20 nM
[81,82]. The concentrations of the tissue inhibitors of metallopro-
teinases (TIMPs) have been also determined to be in the range of
1–10 nM [83]. Yao et al. have determined the concentration of
active MMP2 in a fibroblast cell culture to be 100–350 ng/mL
(1.6–5.6 nM) [11]. However, the distribution and cellular
localization of this protease is not known.
The rate of MMP secretion is also a critical parameter affecting
MMP localization and activity, and depends on cell type and
factors used for cell stimulation. However as most cells, with the
exception of neutrophils, secrete TIMPs in conjunction with
proteases, the protease secretion rate itself is of limited use. For
example, rabbit brain capillary endothelial cells secrete as much
MMP as rabbit synovial fibroblasts, however the MMPs remain
inactive, unlike in the latter, even after activators are present [84].
TIMP secretion is in the range of 1.5?10
5–2?10
5 molecules/cell/h
[85], whereas MMP secretion has been found to range from
,6?10
4–10
7 molecules/cell/h [84,86–89]. In addition, without
continuous protease expression, protease secretion may be a self-
limiting process. The present model uses a simplification of the
MMP dynamics, not taking into account protease synthesis,
activation, inhibition, or internalization. We assume a constitutive
protease expression of 3?10
6 active protease molecules/cell/h. We
expect that this serves as an upper bound to the real value of
protease activity.
Results
A single endothelial tip cell causes little conversion of
soluble VEGF
An analysis of kinetic data of cleavage of VEGF165 by plasmin
yielded a bimolecular rate constant of kP=631 M
21s
21 at 37uC,
which is at the low end of typical ECM enzyme-substrate reactions
for the MMPs (refer to Supplement S1, section S1; Table S1). With low
nM levels of MMPs in vivo, cleavage of VEGF would seem
negligible as its time constant ,100 h. These results motivate us to
study the possibility of pericellular localization of MMPs upon
their secretion.
We considered an isolated tip cell secreting 3?10
6 active
protease molecules/h in a 3D reaction-diffusion model (Fig. 2).
As a reference, we considered the sprout to be immersed in an
initial VEGF concentration field of 1 pM. Note that VEGF levels
are depleted to ,0.988 pM at the tip cell due to internalization
from the 10
4 VEGFR2/cell along the sprout length (Fig. 2C).
Assuming that the secreted proteases are not inhibited or
inactivated, a single cell secreting proteases in isolation provides a
very low proteolytic load (,0.31 nM in the available pores) at the
secreting cell’s surface (Fig. 2A, D). Additionally, due to the
intrinsically slow kinetics of VEGF proteolysis, [VEGF114]i s
present at negligible levels, 2.4?10
24 pM (Fig. 2B, E), relative to
the initial soluble VEGF. As a result, the VEGF165 distribution is
barely altered by the cell’s secretion of proteases (Fig. 2C). The
total soluble VEGF distribution (VEGF165+VEGF114) is not
affected by proteases.
Figure 2. VEGF cleavage due to protease secretion from the tip cell of a vessel sprout. We considered the proteolysis of free and bound
VEGF165 to VEGF114 by secretion of active protease uniformly from the tip cell surface at a rate of 3?10
6 molecules/h. The distributions of protease,
VEGF114, and VEGF165 are shown in A–C. We note that the VEGF165 distribution is virtually unaltered by the secreted proteases. Effects of degradation
of protease activity (kdeg=0,10
24,o r1 0
22 s
21) on pericellular protease and VEGF114 (D–F). F, effect of boundary placement on pericellular VEGF114.
doi:10.1371/journal.pone.0011860.g002
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conversion. Increasing the space around the single tip cell
increases the total VEGF114 levels found in its vicinity (Fig. 2F)
by increasing the total amount of protease a VEGF165 molecule
originating at the boundary must diffuse through (in the limit of an
infinite domain, there would be 100% conversion). Imposing
protease degradation to mimic the effects of inhibition (as
performed in [19,53]) significantly decreases pericellular VEGF114
levels (Fig. 2 D–F).
While protease levels reached only 0.3 nM at the cell surface in
our model, hindering basement membrane diffusion by increasing
its thickness or decreasing the diffusivity may be able to increase
pericellular protease levels and subsequently increase VEGF
conversion. We find that pericellular protease levels are relatively
sensitive to the basement membrane thickness and diffusivity
(noticeable changes in its concentration begin at DBM/DECM,0.1).
However, as the basement membrane diffusivity decreases, the
increase inprotease levels does not lead to a concomitant increase in
VEGF cleavage, shown by cleaved VEGF not becoming significant
until the basement membrane diffusivity reached 1/10,000
th of the
ECM diffusivity (,0.01 mm
2/s) (Fig. 3).Thus, our model shows that
the shape of the basement membrane has negligible effects on
overall VEGF transport for physiologically realistic basement
membrane properties (Table 1). Removing the basement mem-
brane over the entire tip cell decreased MMP levels by ,5% but
decreased VEGF conversion by only ,0.04% (not shown).
Further localization of MMP activity, e.g. to specific micro-
domains on the tip cell, may also increase local MMP
concentrations and VEGF cleavage. To test this, we concentrated
the entire MMP secretion to the leading edge of the tip cell.
Similar to the above trends, increases in local MMP levels were
substantial (to ,5.5 nM) while increases in cleaved VEGF were
not (not shown).
Cell-surface proteases can deplete matrix-bound but not
soluble VEGF
Cell-surface association may potentiate the strength of proteases
against VEGF. To test this, we considered proteases now tethered
to the cell surface that can react with VEGF165 and VEGF165-
HSPG present in the basement membrane layer (Fig. 4A). This
proteolysis mechanism would likely also apply to VEGF bound to
cell-surface HSPGs, which is a more relevant scenario for a tip cell
lacking a basement membrane.
As a baseline, we consider the tip cell having 10
5 active cell-
surface proteases [50]. With an initial background soluble
[VEGF165] of 1 pM, proteolysis leads to the formation of only
3.6?10
23 pM cleaved VEGF at the cell surface (not shown). VEGF165
levels in the basement membrane dropped by an identical amount,
indicating that VEGF165 levels in the ECM, and thus VEGF165-
HSPG levels in the ECM, are not significantly altered (not shown).
Unexpectedly, we notice a very sharp depletion of basement
membrane VEGF165-HSPG (from 540 pM to 160 pM) (not shown).
The sensitivity of VEGF165-HSPG in the basement membrane
to cell-surface proteases is more poignantly captured by testing a
range of protease concentrations (Fig. 4B). The basement
membrane soluble VEGF fractions do not noticeably change over
this range, with their conversion only being significant when the
tip cell expressed ,10
10 cell-surface proteases (Fig. 4C) (VEGF165
conversion=69.5%, VEGF165-HSPG conversion=100%), an
unphysiological level.
To understand why basement membrane VEGF165-HSPG
depletion occurs despite any noticeable depletion in VEGF165
itself, we turned to an analytical analysis of VEGF165 diffusion,
binding, and proteolysis at the cell surface (refer to Supplement S1,
section SVI.1; Fig. S3). We find that the difference in the
susceptibilities of VEGF165 and VEGF165-HSPG to cell surface
proteolysis stems from differences in their rates, per molecule basis,
of being replenished after proteolysis. While VEGF165 is quickly
replenished by diffusion (at a rate 1059 s
21), VEGF165-HSPG is
replenished only as quickly as another complex can dissociate (i.e.
koff=0.01 s
21). In our model, the rate of proteolysis per molecule
VEGF is kP?[P]=0.0236 s
21 ([P] is the effective concentration of
10
5 proteases/cell in the available pores, or 37.5 mM).
Extracellular protease accumulation can account for the
proteolysis of VEGF
As we have shown that an isolated cell is unable to alter its local
soluble VEGF concentration, we attempted to simulate the
proteolytic contribution of other cells by simulating VEGF release
in a spatially constrained environment. We assume the modeled
sprout is one of several sprouts separated by 100 mm (which is
mathematically represented by a reflecting boundary at r=50 mm)
simultaneously migrating towards a distant VEGF source (e.g. tumor)
(see Methods, Geometrical and Transport Parameters). We assume that a
VEGF gradient is established through a balance of VEGF secretion
in front of the sprout and VEGF clearance behind the sprout (see
Methods, Implementation; Table 2) (Fig. 5A). Since we assume protease is
secreted simultaneouslyby numerous cells, wearenot concerned with
its precise distribution; instead, we are concerned with its mean level
and, for simplicity, used a uniform protease concentration field,
which does not affect our results (not shown).
At a physiological protease level of 10 nM, the conversion of
soluble VEGF165 is predicted to be approximately 27% (0.97 pM
to 0.71 pM), however the total soluble VEGF is unchanged due to
Figure 3. Effects of basement membrane thickness and
diffusivity on cell-surface VEGF proteolysis. We studied the role
of basement membrane (BM) diffusion on protease accumulation and
VEGF conversion, in the absence of VEGFR2 and at domain size of
1200 mm. VEGF conversion at the cell surface does not reach
appreciable levels unless DBM is made significantly smaller than DECM
(at 10
24-fold). A ten-fold decrease in diffusivity is equivalent to a ten-
fold increase in basement membrane thickness. We note that the sum
of VEGF165 and VEGF114 is a constant 1 pM at all conditions. The
conditions for which basement membrane dynamics dominates the
cell-surface concentration of VEGF are demarcated roughly by the
intersection points of the dotted blue lines with the VEGF114 and
protease curves.
doi:10.1371/journal.pone.0011860.g003
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VEGF165 is in dynamic equilibrium with HSPG, the total amount
of VEGF165-HSPG decreases by the same relative amount as
VEGF165 does (Fig. 5B, D), leading to a decrease in the total
VEGF (i.e. bound + soluble) present.
We also find that HSPGs significantly increase VEGF165
conversion to VEGF114 (Fig. 5D, E), which was also seen in our
previous results. To analyze this behavior, we derived effective
rates for VEGF proteolysis, internalization, and clearance (refer to
Supplement S1, section SVI.2). We find that HSPGs do not increase
the effective rate of VEGF proteolysis, e.g. by providing additional
sites for cleavage. Instead HSPGs increase the time VEGF spends
in the proteolytic environment, by decreasing the effective VEGF
clearance and internalization ,33-fold in our model. Conse-
quently, our results imply that mechanisms that would increase
VEGF clearance or internalization, e.g. increased VEGFR2
expression, would cause VEGF molecules to spend less time in
the interstitium and decrease VEGF conversion (not shown).
We can similarly use this analysis to estimate the necessary
protease concentration for VEGF proteolysis in vivo. The useful
measure to determine VEGF cleavage in any physiological system
is the total clearance rate of a VEGF molecule (i.e. the sum of
nonspecific and receptor-mediated mechanisms). Experimental
studies indicate a VEGF half-life in the plasma of ,1 h [42].
Assuming kP=631 M
21s
21, ,305 nM protease would result in
50% VEGF cleavage. These protease levels are however
significantly greater than what is expected to be found in vivo.
Discussion
In this study, we developed a computational model of the
cellular proteolysis of VEGF. The model includes the secretion of
Figure 4. Cell-surface mediated VEGF proteolysis. To test VEGF165 conversion via cell-surface proteases, we restricted a specific number of
proteases to the basement membrane layer of the tip cell (A). VEGF165 cleavage can occur either via direct encounter with a protease or after an initial
complexation with HSPG, both at kP=631 M
21s
21.A t1 0
5 proteases affixed to the tip cell, pericellular VEGF114 became ,3.6?10
23 pM while VEGF165
decreased by the same amount; in contrast, VEGF165-HSPG in the basement membrane layer decreased from 540 pM to 160 pM (not shown). B, range
of cell-surface protease densities. Note lack of VEGF165 conversion. C, pericellular VEGF distribution for 10
10 cell-surface proteases (significantly higher
than physiological levels). Note that total soluble VEGF (dashed line) is unaltered, even as VEGF165 undergoes significant depletion.
doi:10.1371/journal.pone.0011860.g004
Figure 5. VEGF cleavage in a spatially bounded domain with VEGF gradient. Multi-cellular protease secretion was assumed to represent a
uniform protease distribution at 10 nM. In the absence of protease, basal VEGF levels were 1 pM, 5%/40 mm VEGF165 gradient (at z=0) (A). B, C, the
steady-state VEGF distribution. The total soluble VEGF (soluble VEGF165+VEGF114) is exactly identical to the basal state (A). D, E, we considered a range
of protease (0–100 nM) and HSPG concentrations (750 nM, 7.5 mM). VEGF165 (green), VEGF114 (red), total soluble VEGF (blue), and HSPG bound
VEGF165 conversion (black) (E).
doi:10.1371/journal.pone.0011860.g005
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proteolysis to VEGF114, and VEGF clearance. While simplified, it
allows us to make broad conclusions regarding the extent and
determinants of VEGF proteolytic release.
Kinetic fitting of experimental data shows that VEGF cleavage by
plasmin is a slow reaction. Using a reaction-diffusion model of a
cellular microenvironment, and after overestimating protease
secretion (3?10
6 active protease molecules/cell/h) and accounting
for mechanisms of increased cell-surface MMP localization, we find
that an isolated cell would have difficulty in causing significant VEGF
conversion. Reconciling the in vivo observation of VEGF cleavage
requires a mechanism of protease accumulation, e.g. geometric
constraints and/or simultaneous protease secretion by numerous
cells. We thus propose VEGF cleavage is not mediated by single cells
but rather by the collective behavior of a tissue, dependent upon total
cell density and the whole-tissue MMP concentration.
Our results show that the release of VEGF, mediated by the
proteolytic cleavage of matrix-bound VEGF165 to soluble VEGF114,
does not increase total soluble VEGF levels at steady state as long as the
total clearance (clearance and internalization) of VEGF165 and
VEGF114 are indistinguishable, which was assumed in our model
and was approximately observed in the plasma of mice [42]. In
contrast to soluble VEGF, HSPG-bound VEGF levels are lowered in
the presence of proteases, reflecting the reduced levels of soluble
VEGF165 in equilibrium with HSPGs. This effect was especially
notable close to the cell surface, for VEGF165-HSPG within the range
of cell-surface proteases. Thus, we suspect that matrix-bound VEGF
may represent a more responsive signaling modality than free VEGF,
at least to the presence of proteases. This coupled with a recent finding
that matrix-bound VEGF induced prolonged receptor activation
compared to soluble VEGF [16] suggests that proteases may be
altering angiogenesis primarily through their effects on matrix-bound
VEGF. Another interesting possibility to consider is the direct
proteolysis of receptor-bound VEGF by cell-surface proteases; due to
receptors’ slower VEGF dissociation rates (koff=10
23 s
21)c o m p a r e d
to HSPGs (koff=10
22 s
21), they may mediate an even more sensitive
protease response curve than that seen with HSPGs (Fig. 4B).
HSPGs are thought to reduce the effective rate of VEGF diffusion
by rapidly binding VEGF (theoretically-estimated characteristic time
of 3.1 s yielding a 32.5-fold lower effective diffusivity, Supplement S1
Section SVI.2).Our model predicts that HSPGsincrease the proteolytic
conversion of matrix-binding VEGF isoforms by increasing the
residence time of a VEGF molecule in a tissue’s proteolytic
environment. As a result, assuming each VEGF isoform has similar
susceptibility to proteases, cleavage of non-HS binding VEGF
isoforms (e.g. VEGF121,V E G F 165b) would be expected to be
negligible, while cleavage of VEGF145 [90] and VEGF189 [4,23]
could be even greater than VEGF165. In contrast, factors that
increase total VEGF clearance, e.g. VEGFR-mediated internaliza-
tion, result in decreased proteolytic conversion.
Our model makes several important assumptions that are worth
clarifying, the most important being the consideration of steady
state. Steady state is justified in that the net rate of VEGF
clearance in vivo is much faster (and hence VEGF reaches a
dynamic equilibrium) than structural changes such as vessel
reorganization and angiogenesis, which may take several hours to
days and are thus relatively static. While our system’s overall time
scale was ,10 h (refer to Supplement S1, section SVI.2), we did not
represent the full extent of the vasculature and vessel-mediated
internalization in our model. Our previous computational model,
representing the whole body microenvironment, estimated a
VEGF tissue clearance rate of ,30 min, primarily due to
receptor-mediated internalization [62], consistent with VEGF
kinetics in plasma with t1/2,1 h [42]. Steady state can also be
used to determine the time-averaged behavior of tissues, as
individual cellular events (e.g. protease secretion by an infiltrated
neutrophil and subsequent VEGF release) may be stochastic and
transient in nature. This view, in turn, is justified by our results,
which show that proteolysis is most likely due to the collective
independent behavior of a group of cells.
Another important assumption we made was that HSPGs do
not protect VEGF against proteolysis, as seen by Lee et al. for
MMP3 [3]. However, other proteases-substrate reactions, e.g.
MMP9 and VEGF164 [3], or plasmin and bFGF [91], might be
sterically blocked by heparan sulfates or HSPGs. In our model,
VEGF protection by HSPGs would significantly decrease the
VEGF conversion, further raising the necessary in vivo protease
concentration required to explain the significance of VEGF
proteolysis. The role of such proteases may instead be the cleavage
of HSPG core protein to enable diffusion of HS-bound VEGF,
which was shown for MMP9 in a HT29 colon carcinoma spheroid
model [8]. A future analysis of the mechanisms of different
proteases should also take into account protease binding to the
ECM, which could result in significantly higher tissue protease
levels not reflected in serum or plasma levels.
Finally, an endothelial tip cell is structurally more complex more
than the simple cylindrical tube we have assumed [13]. Tip cells
actively project lamellipodia and filopodia, which increase the
surface area of a tip cell, increasing the contact with VEGF in the
ECM and possibly facilitating cleavage. Cavities between these
extensions may also serve as protected pockets where VEGF and
protease activity can be even further localized. In addition, tip cells
are more directly exposed to the ECM due to a lack of an intact
basement membrane. Our results however suggest that none of
these mechanisms significantly enhance VEGF cleavage. An
increased tip cell surface area and a loss of a basement membrane
facilitate VEGF diffusion away from the cell surface, decreasing
the amount of cleaved VEGF present (refer to Fig. 3; Supplement S1
section SVI.1). We simulated concentration of proteases to
microdomains and the presence of concave pockets (not shown);
local proteases concentrations do increase, however, not enough to
increase pericellular VEGF cleavage to significant levels (not shown).
TheconventionalviewofVEGFreleaseisthatitisa cell-directed,
localized process. VEGF165 and VEGF189 are typically thought to
be tightly bound to HSPGs (e.g. forming deposits of VEGF
[3,13,53]) that are then rapidly released by pericellular proteolysis,
forming an effective autocrine loop, allowing efficient receptor
activation of the same cell [19,53]. Overall, our results showthat the
rate of VEGF diffusion is exceedingly high to support these views:
VEGF deposits and the cell-directedness of proteolysis
While the affinity of VEGF165 to HSPG is high (24 nM in our
study), the dissociation rate is rapid (koff=0.01 s
21) and VEGF165
is always near dynamic equilibrium with HSPGs (t=3.1 s). This
indicates that VEGF165 should not form any stationary deposits as
they will quickly equilibrate. Deposits of VEGF could instead
reflect spatial inhomogeneities in the underlying HSPG itself,
which would have a longer lifetime due to the decreased motility of
HSPG within the ECM. These inhomogeneities may be important
to cellular guidance [53]. In addition, since VEGF proteolysis is
slow, VEGF165 is more likely to simply dissociate than be cleaved
and released in a directed manner by a cell. Directed proteolysis
could occur for covalently tethered VEGF [28] and possibly for
VEGF189 [92], which has high affinity for ECM.
Localization and extent of pericellular proteolysis
Pericellular proteolysis is significant for many processes
[3,49,51] and we have previously confirmed this for MT1-MMP
VEGF Release Model
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argue that this is not the case for catalyzing VEGF165 release (or
more generally for any ligand of similar diffusivity) (Figs. 2, 3, 4).
This is due to VEGF having a much faster rate of replenishment
due to diffusion than can be expected for collagen by cell
migration [50] (i.e. DaVEGF-Proteolysis%DaCol1-Proteolysis,1). More-
over, pericellular VEGF cleavage remains insensitive to changes in
MMP localization brought about by changes in basement
membrane diffusion (Fig. 3) and microdomain sequestration of
protease secretion (not shown). Due to physiological limits in the
number of proteases a cell can secrete and the rate of VEGF
cleavage, proteases cannot be both localized to an isolated cell and
induce significant VEGF cleavage at the same time. Instead, Fig. 5
shows that for cleaved VEGF to be significant around a cell of
interest, the majority of VEGF proteolysis leading to that cleaved
VEGF must be occurring outside of the cell’s vicinity. This is not
to say that proteolysis occurs only in the surrounding ECM; it can
also be occurring on the surface of other cells, which was shown by
Lee et al. using a coumarin-conjugated VEGF peptide [3]. This
also implies that cleaved VEGF must behave in a dispersive
fashion, which is discussed in the next section.
Efficiency of autocrine capture
Even if VEGF is cleaved and released at the cell surface,
diffusion away from the cell surface is significantly faster than
VEGFR2 binding and internalization (Supplement S1, section SVI.1):
at steady state, the capture probability was only 0.8% for our tip
cell with 10
4 VEGFR2 (Supplement S1, section SVI.1; Fig. S3B). In
contrast to our results, a previous analysis [55] demonstrated much
higher efficiencies (10–65%) for autocrine capture; however, these
probabilities would only arise if the interstitial space were as
structurally dense as basement membranes and VEGF diffusivities
were as low as 0.1–1 mm
2/s [54]. Even if we assume that the
released VEGF was not cleaved and it can still bind to the ECM,
we show that the diffusive hindrance due to HSPGs does not
increase autocrine capture (only diffusive hindrances due to matrix
tortuosity and water/fiber hydrodynamic interactions [93] yield
increases in autocrine capture). By sequestering VEGF away from
receptors, HSPGs decrease the transient capture of VEGF by
VEGFR2 (not shown) and have no effect at steady state. Finally, our
results imply that autocrine VEGF release and recapture would be
even less likely in the presence of interstitial flow. This contradicts
the hypothesis of a previous finding that the autocrine detection of
convection-driven gradients of proteolytically-released VEGF may
enhance capillary morphogenesis [19].
Autocrine capture can be increased by several mechanisms,
including increasing the thickness of a surrounding basement
membrane (Fig. 3). For a tip cell, which has at best a tenuous
basement membrane, capture is more likely to be increased by an
increase in receptor expression [13] and by spatially restricting
receptor and protease activity to discrete microdomains on the cell
surface (Fig. 6). For example, a uniform distribution of 10
5 NRP1
and 10
5 VEGFR2 can extend the a tip cell’s capture of VEGF165
to ,30%, while clustering all receptors to the leading edge of the
tip cell further increases capture to ,87%. Capture of cleaved
VEGF is weaker than that of VEGF165 due to a lack of NRP1-
binding, and for typical receptor concentrations found in
HUVECs (Fig. 6C, gray bars), remains negligible. This implies
that VEGF isoforms released through ECM cleavage (thus still
maintaining their NRP1- and cell-surface HS-binding domains)
will experience higher autocrine capture probabilities than VEGF
released through VEGF cleavage.
Overall, proteolysis can be cell-directed only for strongly-
matrix-binding isoforms, while further autocrine activity can only
Figure 6. VEGF receptors on autocrine capture by a tip cell. We estimated autocrine capture probabilities for a VEGF molecule placed at the
cell surface. Overall capture probabilities through all receptors were estimated using a continuum approximation, Pcap=12[VEGF]r=Rcell/[VEGF]r=Inf.
We assumed an isolated cell (case 1, with no receptors on the stalk cells), set far-field [VEGF]=1 pM, and measured cell surface [VEGF] after the steady
state in VEGF internalization. Capture probability by VEGFR2 was further approximated by multiplying Pcap by the ratio of receptor-bound VEGF
bound to VEGFR2. A, B, schematic of VEGF165 and VEGF114 interactions with VEGFR1, VEGFR2, and NRP1. Equations for the full reaction network are
given in Supplement S1, section SII. C, capture probability of VEGF165 (i) and VEGF114 (ii) by VEGFR2. We considered two tip cell receptor distributions:
uniform coverage and localization to the front edge (microdomain). Gray bars indicate receptor numbers recently measured on HUVECs (P.
Imoukhuede, personal communication); other colors represent reference cases.
doi:10.1371/journal.pone.0011860.g006
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receptor-binding domains (Fig. 7A). The extent of VEGF cleavage
is significant only at higher cell densities and cleaved VEGF
necessarily acts in a dispersive, paracrine manner (Fig. 7B).
Since VEGF cleavage is a multi-cellular phenomenon, its
effectiveness for any single cell capable of sensing VEGF depends
on the total density of cells secreting or cleaving VEGF, as well as
overall tissue clearance and receptor-mediated uptake rates. While
our model did not explicitly account for the multiple cell types
involved in angiogenesis (e.g. macrophages, pericytes, and paren-
chymal cells) [32,94], our results further support the concept that
numerous cells and cell types are involved in the angiogenic
response. In cell cultures, a low cell density environment, we expect
a low fraction of existing VEGF to be released (i.e. low conversion),
shown experimentally in[14], though inat leastonecase, significant
levels of cleaved VEGF were observed in the conditioned media of
ovarian cancer cell lines [33]. At high cell densities, such as in vivo
(e.g. tumors, oxygen-induced retinopathy), VEGF conversion could
be significant (resulting in a significant fraction of plasma VEGF
being cleaved) [3,17]. However, our preliminary estimates require
,305 nM active protease to account for this high level of cleaved
VEGF, concentrations that are greatly in excess of physiological or
pathological protease levels. To resolve this paradox, it must be
determined whether all known proteasesaretaken into account (e.g.
matrix-sequestered MMPs), as well as to determine the accuracy of
our estimated kinetic parameters of VEGF cleavage.
Conclusion
We developed a computational model to simulate the proteolytic
cleavage of VEGF in the vicinity of an endothelial sprout. We found
that VEGF proteolysis by plasmin is slow compared to other
proteolysis reactions. In order for VEGF conversion to be significant,
we required a model where protease production is not limited to a
single cell. Our results suggest autocrine effects can only be supported
by ECM-cleaving VEGF release, which would preserve VEGF’s
ability to bind to co-receptors, while paracrine effects are expected for
VEGF-cleaving VEGF release. Localization of proteases and
receptors to cell surface microdomains can significantly improve
autocrine capture, however it has no significant effect on VEGF
proteolysis. Our analysis also shows two distinct roles for HSPGs: they
increase VEGF conversion by decreasing the overall VEGF clearance
rate in tissues and also provide a unidirectional signaling modality in
the presence of proteases. Future experiments should test the cell
density dependence on VEGF cleavage as well more accurately
estimate the quantity of proteases present in vivo.
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